Register in advance for this webinar:
After registering, you will receive a confirmation email containing information about joining the webinar.
Monday, May 24th 7:00 p.m. EDT.
As a result of participating in this activity, learners will be able to: Review the outcomes for different subsets of patients with pancreatic cancer, recognize the potential relevance of neoadjuvant chemotherapy and radiotherapy for resectable and unresectable pancreatic cancer, and discuss the use of evidence-based national guidelines and prognostic indicators, such as the AJCC staging system
The target audience for this presentation: medical oncologists, surgical oncologists, radiation oncologists, gastroenterologists
CME statement:
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
USF Health designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
USF Health (provider number 2970) is an approved provider of continuing education for nurses through Florida Board of Nursing. This activity has been approved for 1.0 contact hours.
View related document for accreditation information.
CONTACT
If you have any questions or credit related inquiries, please contact USF Health at cpdsupport@usf.edu
Published
May 3, 2021
Created by
Presenters
Andreas Karachristos, FACS, MD, PhD
Chief of Surgical Oncology
Hepatobiliary and Pancreatic Surgery
Professor of Surgery
Department of Surgery
University of South Florida
Dr. Andreas Karachristos specializes in hepato-pancreato-biliary(HPB) or the care of the liver, pancreas, bile duct and gallbladder.
Professor & Chair, Radiation Oncology
USF Health Morsani College of Medicine
Director of Research
Tampa General Hospital